NattoPharma (NATTO)

[TekBot]

NattoPharma ASA Exercise of options

Oslo, Norway (11 June 2020)

SPW, Inc. represented by Peter Stahl has exercised 25 000 options granted to
…

Vis børsmeldingen

him.

Following the exercise of the option SPW, Inc. will hold 25 000 shares in
NattoPharma ASA.

Based on the power of attorney granted at the annual general meeting of
NattoPharma ASA on May 29, 2019, the Board of Directors of NattoPharma has in
board proceedings June 11, 2020 approved a share issue of 25 000 new shares,
each with a face value of NOK 3 per share.

Price to be paid for each share is NOK 9,00 per share. The share issue is
expected to be completed within end of June 2020.

As a result, the share capital will be increased by NOK 75 000. After completing
the share issue the Company’s new share capital will be NOK 58 619 799 divided
into 19 539 933 shares, each with a face value of NOK 3.

---

For more information, please contact:

Robert Schrama, CFO

E-mail: robert.schrama@nattopharma.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities

Kilde

[holmes]

London

NattoPharma / Kappa stämmer NattoPharma / Fult spel av Kappa

idag 09:27 IP: ol8rqDifs

Patentet som Kappa hänvisar till är inte ens godkänt och kanske aldrig blir godkänt.
Det enda Kappa har gjort är att skicka ett brev till NattoPharma med hot om att eventuellt i framtiden, om patentet blir godkänt inom EU, anklaga NattoPharma för att bryta mot detta patent.

Att samtidigt som man gett ett skambud börja hota med stämning, på mycket lösa grunder, är inte seriöst. Detta är ett försök att lura mindre aktieägare att sälja sina aktier alltför billigt.

[Savepig]

Her må klage til rette myndighet være på sin plass

[FeitaInc]

Jeg er ikke jurist og min forståelse av patent-rett er på ingen måte fullstending, men mener å ha lest flere steder at dersom to selskaper gjør en ting på helt samme måte og begge kan dokumentere at de har begynt med det samtidig/før den ene parten søker patent, så vil ikke den ene kunne patentere det og så kreve lisensrettigheter av den andre. da faller bruken av den parten som ikke har patentet under prior art eller noe sånn. (om det er noen som vet mer her, er det bare å rette/legge til.)

Om det derimot er noen flere aktører som begynner å gjøre det på samme måte, etter patentet er innvilget eller søkt om, kan den parten som har fått innvilget patentet kreve lisensavgift.

det er slik jeg leser svaret fra NattoPharma, altså
"...The Board has carefully assessed the letter from Kappa, and the Board is comfortable with the position of NattoPharma and that the content of Kappa's letter will not have a material negative...".

[Quadruple]

Detta är ett försök att lura mindre aktieägare att sälja sina aktier alltför billigt.

Og det ser de ut til å lykkes med. Kursen er nå nede på samme nivå som det fiendtlige budet.

[Oxion]

Dette er direkte skammelig, kappa har surfet på nattopharmas forskning i alle år!!!
Dette burde få frem en faen i alle ansatte, for Nattopharma har mye bedre kort på handa enn Kappa.
Men en vet aldri med Natto, sitter noen Røvere på innsiden der👍

[holmes]

Fikk man ristet ut de kortsiktige i dag?

[TekBot]

Trading update

Oslo, Norway (12 June 2020) - NattoPharma continues to see a strong demand for
our products during the second quarter, and we are experiencing Q2 revenue to be
in the range of NOK 44-54 million resulting in a H1-2020 revenue in the range of
…

Vis børsmeldingen

NOK 100-110 million. This is more than 70% growth compared to H1-2019. The Adj.
EBITDA margin is expected to be in excess of 15% for H1-2020, compared to the
current guiding of 10-15% for the full year.

The current performance builds on our confidence to deliver on the guiding for
the full year as communicated during the Q1 release. During the second quarter
we have continued to see a strong demand for dietary supplements and in
particular our clinically validated products.

NattoPharma will provide more detailed insight and guidance during the H1
release scheduled at July 15[th], 2020.

---

For more information, please contact:

Robert Schrama, CFO

E-mail: robert.schrama@nattopharma.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities

Kilde

[TekBot]

Trading update

Oslo, Norway (12 June 2020) - NattoPharma continues to see a strong demand for
our products during the second quarter, and we are experiencing Q2 revenue to be
in the range of NOK 44-54 million resulting in a H1-2020 revenue in the range of
…

Vis børsmeldingen

NOK 100-110 million. This is more than 70% growth compared to H1-2019. The Adj.
EBITDA margin is expected to be in excess of 15% for H1-2020, compared to the
current guiding of 10-15% for the full year.

The current performance builds on our confidence to deliver on the guiding for
the full year as communicated during the Q1 release. During the second quarter
we have continued to see a strong demand for dietary supplements and in
particular our clinically validated products.

NattoPharma will provide more detailed insight and guidance during the H1
release scheduled at July 15[th], 2020.

---

For more information, please contact:

Robert Schrama, CFO

E-mail: robert.schrama@nattopharma.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities

Kilde

[FeitaInc]

Boom!

Så ser ut som om det ikke bare var snakk om «pull forward demand» forrige kvartal. Super oppdatering!

[Savepig]

Haha love it!

[Savepig]

NattoPharma venter kraftig vekst - nå har aksjen doblet seg

Man må ta chart tilbake til 2015 for å se sånne kurser.

NattoPharma bare

[holmes]

Tror vi langsiktige får betalt til slutt

[holmes]

Hadde vært digg med innsidekjøp, burde være mulig med tanke på dagens oppdatering?

[tooeasy891]

Det får vi håpe på. Kan bli en veldig fin vekst om disse estimatene slår til:
The global vitamin K2 market is estimated to touch a valuation of USD 228.27 million by 2023 , as per the latest findings of Market Research Future (MRFR). It is predicted to register 31.08%% CAGR over the forecast period (2018-2025).

[TekBot]

Extension of the offer period for the unconditional offer to acquire up to 11.0% of the shares in NattoPharma ASA

NOT FOR DISTRIBITION IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

Reference is made to the stock exchange announcement on 28 May 2020 where Kappa Bioscience AS (“Kappa”) announced an unconditional offer to acquire up to 2,127,573 shares in NattoPharma ASA, at a price of NOK 12.75 per share on a first come first serve basis (the “Offer”). Kappa has resolved to extend the offer period until the earliest of the date Kappa has acquired 2,127,573 shares and 26 June 2020. Shareholders who wish to sell shares should contact Carnegie AS, phone +47 22 00 93 40, email kappa@carnegie.no.
…

Vis børsmeldingen

Kappa further announced an intention to make a voluntary offer to acquire all the outstanding shares in NattoPharma ASA at an offer price of NOK 12.75 per share provided that the conditions for launch of the Voluntary Offer set out in the announcement are fulfilled, including access to due diligence. NattoPharma ASA announced on 29 May 2020 that it is currently of the view that it will not allow Kappa access to conduct a due diligence and Kappa is considering its options in light of this. Kappa continues to believe there is a strong financial, market, and strategic rationale for a combination with NattoPharma ASA and looks forward to presenting this view to interested parties.

For further information, see the stock exchange announcement dated 28 May 2020.

About Kappa Bioscience AS

Kappa Bioscience AS is a Norwegian entity founded in December 2006. Utilizing advanced production technology based on a strong patent portfolio, Kappa has secured global leadership in the production and development of vitamin K2, which is one of the fastest-growing health ingredients worldwide. Kappa is currently the leading vendor of vitamin K2 for use in various formulations, and Kappa’s leadership in the vitamin K2 market is further exemplified by its recent patent expansion in the production of vitamin K2 as pure MK-7 (menaquinone-7). While vitamin K2 provides the cornerstone for Kappa’s business, Kappa also offers a range of bone and heart health category ingredients in several forms and concentrations. A key objective going forward is to make vitamin K2 accessible for the global food supplement and fortified food market. Kappa will continue to serve the market with pure and stable forms of MK-7 products. With regulatory approvals in leading markets, including US self-affirmed GRAS and an NDIN, Kappa’s vitamin K2 MK-7 can be used in most applications, also in conventional foods.

Advisers and contact

Carnegie AS is acting as financial advisor and Advokatfirmaet Wiersholm AS is acting as legal advisor to Kappa in connection with the Voluntary Offer and the Offer.

For additional information please contact:
Egil Greve, President & CEO Kappa Bioscience AS, +47 95 10 95 65, egil.greve@kappabio.com
Stefan Schander Slemdal, Carnegie AS, +47 40 64 04 26, stefan.slemdal@carnegie.no

Kilde

[holmes]

NattoPharma ASA announced on 29 May 2020 that it is currently of the view that it will not allow Kappa access to conduct a due diligence and Kappa is considering its options in light of this. Kappa continues to believe there is a strong financial, market, and strategic rationale for a combination with NattoPharma ASA and looks forward to presenting this view to interested parties.

Kommer de til å foreslå en form for sammenslåing?

[holmes]

Sjelden at jeg følger med på sluttauksjoner i disse dager siden jeg har sluttet å trade aksjer, men i dag boltret jeg meg

Grei sluttkurs, men håpet på litt mer volum i sluttauksjonen

[FeitaInc]

Mulig jeg misforstår hva som står her, men det gir absolutt ingen mening å legge til rette for en “due dilligence” gjennomgang for hovedkonkurrent før Kappa har kommet i en posisjon hvor de enten har mer en 1/3 av aksjene, 1/2 eller helst 90%. Før de eier 10% kan jeg ikke skjønne at de har rett på noen som helst informasjon annet enn den som er offentlig tilgjengelig.

Om de kjøper seg opp til 1/3 og blokkerer eventuelle emisjoner elller andre initiativ som kan gi vekst, kan de vente seg tidenes søksmål fra resten av aksjonærene skullle jeg tro.

[holmes]

Helt klart! Slik jeg tolker den meldingen så ser de på forskjellige alternativ og prøve å selge inn ideen om at Kappa og NattoPharma er en god kombinasjon - hvorfor selge inn den ideen dersom de bare skulle kjøpe ut eksisterende aksjonærer, tenker derfor de kan komme til å foreslå en form for omvendt oppkjøp der man får aksjer i det fusjonerte selskapet dersom man ikke ønsker å selge aksjene sine. Men det er såklart bare min subjektive spekulasjon.